LyondellBasell
LYB
$73.27
-0.64%
LyondellBasell Industries N.V. is a global petrochemical producer, operating in the United States, Europe, and Asia, with a core business in manufacturing polypropylene, polyethylene, and propylene oxide used in a vast array of consumer and industrial end products. The company is a market leader, holding the title of the world's largest producer of polypropylene, which provides it with significant scale and a competitive identity as a low-cost operator in the cyclical chemicals industry. The current investor narrative is dominated by the severe downturn in the chemical cycle, evidenced by a recent dividend cut and quarterly losses, juxtaposed against a powerful stock price rally driven by a de-escalation of Middle East tensions and a subsequent crash in oil prices, which could ease input cost pressures and revive margins.…
LYB
LyondellBasell
$73.27
Related headlines
Investment Opinion: Should I buy LYB Today?
Rating: Hold. The core thesis is that LYB is a compelling cyclical recovery bet whose powerful rally has largely priced in the near-term upside, warranting caution until clearer signs of fundamental improvement emerge.
The Hold rating is supported by conflicting data points: the extreme valuation discount (PS of 0.46), strong technical momentum (+53% in 3 months), and robust FCF ($2.26B TTM) are offset by severe fundamental deterioration (-25% YoY revenue growth, net losses) and the recent dividend cut signaling sustained pressure. The forward P/E of 13.1x, based on analyst estimates, is reasonable for a recovery but hinges on achieving the average EPS of $5.93, which is highly uncertain given the wide forecast range ($4.26 to $7.79).
The two biggest risks are a delay in the earnings recovery beyond 2026 and a technical reversal from overbought levels. This Hold would upgrade to a Buy if the stock pulls back to the $60-$65 range (offering a better margin of safety) and/or Q2/Q3 2026 earnings show a definitive quarter-over-quarter improvement in gross margins above 10%. It would downgrade to Sell if revenue continues to decline YoY and quarterly losses persist into Q3 2026. Relative to its own distressed valuation history and the current cycle trough, the stock appears fairly valued, balancing deep-value potential against near-term operational headwinds.
Sign up to view all
LYB 12-Month Price Forecast
LYB is a classic 'show me' story at a cyclical inflection point. The market has aggressively front-run a recovery, lifting the stock 53% in three months on geopolitical and oil price catalysts. However, the underlying fundamentals have yet to confirm the turnaround, with the company still reporting losses. The neutral stance reflects this disconnect; the risk/reward is balanced until the next few earnings reports provide clarity. The stance would upgrade to bullish on confirmation of margin recovery and a return to profitability in the upcoming quarters. It would turn bearish if the stock breaks below key support at $66.27 (the April 17 low) on worsening fundamental news.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LyondellBasell's 12-month outlook, with a consensus price target around $95.25 and implied upside of +30.0% versus the current price.
Average Target
$95.25
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$59 - $95
Analyst target range
Analyst coverage is limited with data for 10 analysts, but specific Buy/Hold/Sell distribution and consensus target price are not provided in the dataset, making a precise consensus sentiment calculation impossible. The estimated EPS range for the forward period is wide, from $4.26 to $7.79 with an average of $5.93, indicating significant uncertainty about the pace and magnitude of an earnings recovery. The recent institutional ratings show a mixed but generally cautious picture, with actions in March 2026 including upgrades from Citigroup (to Buy) and RBC Capital (to Outperform), but also several reiterations of Hold or Neutral ratings from firms like Wells Fargo, Mizuho, and Deutsche Bank; this pattern suggests analysts are divided, with some seeing value after the rally while others remain sidelined, and the wide EPS forecast range signals high uncertainty typical of a cyclical inflection point.
Bulls vs Bears: LYB Investment Factors
The bull and bear cases for LYB are in sharp tension, with the bulls arguing from valuation and momentum while the bears point to deteriorating fundamentals. Currently, the bear case has stronger evidence in the near term, given the concrete data of revenue contraction, net losses, and a dividend cut. However, the powerful rally suggests the market is looking 6-12 months ahead, betting on a cyclical recovery. The single most important tension in the investment debate is the timing of the chemical cycle inflection. If input cost relief from lower oil prices swiftly translates to margin expansion and a return to profitability in H2 2026, the bulls will be validated. If demand remains weak, extending losses and straining the balance sheet, the recent rally will prove premature, and the stock could re-test lower levels.
Bullish
- Extreme Valuation Discount: The stock trades at a trailing Price-to-Sales ratio of 0.46, which is near the absolute bottom of its multi-year historical range. This suggests the market is pricing in peak pessimism regarding the chemical cycle downturn, creating a deep-value opportunity if a recovery materializes.
- Powerful Technical Uptrend: LYB has surged 53.04% over the past 3 months and 61.55% over 6 months, with the current price at $74.99 sitting near the top of its 52-week range. This momentum, driven by a 'peace trade' and crashing oil prices, indicates strong investor belief in a cyclical recovery.
- Strong Free Cash Flow & Balance Sheet: Despite quarterly losses, the company generated $2.26 billion in TTM free cash flow and maintains a robust current ratio of 1.77. The recent dividend cut, while negative for income investors, demonstrates prudent capital allocation to preserve financial health during the downturn.
- Analyst Upgrades Signal Inflection: Recent institutional actions include upgrades from Citigroup (to Buy) and RBC Capital (to Outperform) in March 2026. This shift in sentiment, coupled with a forward P/E of 13.1x based on estimated EPS of $5.93, suggests some analysts see the cycle trough being priced in.
Bearish
- Severe Fundamental Deterioration: Q4 2025 revenue declined 25.33% YoY to $7.09B, and the company reported a net loss of -$140M with a gross margin of just 6.49%. This continues a volatile but negative trend, including a -$892M loss in Q3 2025, confirming a deep industry downturn.
- Dividend Cut Signals Sustained Pressure: The company's drastic dividend reduction, as reported in February 2026, is a clear signal of severe cash flow pressure and management's expectation of a prolonged downturn ('one of the longest downturns in chemical industry'). This removes a key support for income-oriented investors.
- High Leverage Amid Cyclical Losses: A debt-to-equity ratio of 1.58 indicates leveraged operations. Servicing this debt becomes more challenging with an operating margin of -1.08% and negative net income, increasing financial risk if the downturn persists longer than anticipated.
- Price Near 52-Week High After Massive Rally: The stock trades at 89% of its 52-week high ($83.94) after a 53% 3-month surge. This positioning suggests limited near-term upside and high vulnerability to a correction, especially given the recent 1-month pullback of -2.24% and underperformance vs. SPY.
LYB Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +28.61% and a 3-month surge of +53.04%, with the current price of $74.99 sitting near the top of its 52-week range (41.58 to 83.94), representing approximately 89% of that range. This positioning near the highs signals strong momentum but also raises questions about overextension, especially after the recent rally. Recent momentum shows a slight divergence, with a 1-month pullback of -2.24% contrasting the longer-term uptrend, indicating a potential consolidation or profit-taking phase after the explosive gains; this is supported by a relative strength reading of -12.22 against the SPY over the same period, showing short-term underperformance. Key technical support is at the 52-week low of $41.58, while immediate resistance is at the 52-week high of $83.94; a breakout above $83.94 would confirm the bullish trend's resumption, while a breakdown below the recent low of $66.27 (from April 17) could signal a deeper correction. The stock's beta of 0.437 indicates it is significantly less volatile than the broader market, which is unusual for a cyclical materials stock but may reflect its large-cap status and recent defensive rotation.
Beta
0.35
0.35x market volatility
Max Drawdown
-37.1%
Largest decline past year
52-Week Range
$42-$84
Price range past year
Annual Return
+23.8%
Cumulative gain past year
| Period | LYB Return | S&P 500 |
|---|---|---|
| 1m | +0.0% | +7.7% |
| 3m | +27.2% | +9.7% |
| 6m | +61.7% | +11.3% |
| 1y | +23.8% | +27.3% |
| ytd | +65.1% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LYB Fundamental Analysis
Revenue is in a clear declining trajectory, with Q4 2025 revenue of $7.09 billion representing a -25.33% year-over-year contraction, continuing a multi-quarter downtrend from $9.50 billion in Q4 2024; segment data shows the Olefins & Co-Products and Polyethylene segments were the largest revenue contributors at $1.06 billion and $1.68 billion respectively in the latest period, but all segments are facing pressure from the industry downturn. Profitability has deteriorated sharply, with the company reporting a net loss of -$140 million in Q4 2025 and a gross margin of just 6.49%, down from 7.90% in the year-ago quarter; the trend is volatile but negative, swinging from a profit of $175 million in Q1 2025 to a loss of -$892 million in Q3 2025, indicating severe margin compression typical of the bottom of the chemical cycle. The balance sheet shows moderate financial health with a debt-to-equity ratio of 1.58, indicating leveraged operations, but it is supported by a strong current ratio of 1.77 and robust trailing twelve-month free cash flow of $2.26 billion; however, the recent dividend cut signals management is prioritizing balance sheet preservation over shareholder returns amid the cash flow pressures of the downturn.
Quarterly Revenue
$7.1B
2025-12
Revenue YoY Growth
-0.25%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LYB Overvalued?
Given the negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.46, while the forward PS, implied by the current price and analyst revenue estimates, is also low, suggesting the market is assigning a depressed multiple to sales due to the cyclical downturn and poor profitability. Compared to industry averages, specific data is not available in the provided dataset, but a PS of 0.46 is typically considered very low for a major chemical producer, likely trading at a deep discount to the sector, which may be justified by its current loss-making profile but could represent deep value if a cyclical recovery materializes. Historically, the stock's own PS ratio has fluctuated widely, from a high above 4.0 in early 2021 to the current 0.46; this places it near the absolute bottom of its multi-year historical range, which suggests the market is pricing in peak pessimism and fundamental deterioration, potentially creating a value opportunity for investors betting on a cycle recovery.
PE
-18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are elevated. LYB is currently loss-making, with a Q4 2025 net loss of -$140M and a gross margin compressed to 6.49%, down from 7.90% a year ago. This earnings volatility, swinging from a $175M profit in Q1 2025 to a -$892M loss in Q3 2025, creates high uncertainty. While the balance sheet shows a strong current ratio of 1.77 and $2.26B in TTM FCF, the debt-to-equity of 1.58 represents a meaningful burden if the downturn is prolonged, as evidenced by the dividend cut to preserve cash.
Market & Competitive Risks center on its cyclical nature and valuation. The stock's 3-month surge of 53% has pushed it to the top of its 52-week range, increasing its vulnerability to profit-taking and multiple compression if the anticipated recovery stalls. Its low beta of 0.437 is atypical and may not hold if recession fears resurface, exposing the stock to sector-wide de-rating. Competitively, as a low-cost leader, it is better positioned than peers, but the entire industry faces headwinds from potential oversupply and weak global demand, which could delay the margin recovery currently priced into the rally.
Worst-Case Scenario involves a 'double-dip' in the chemical cycle where lower oil prices fail to stimulate sufficient demand, keeping margins depressed for multiple quarters. This could lead to consecutive quarterly losses, a credit rating downgrade due to sustained high leverage, and a breakdown of the recent technical rally. The realistic downside could see the stock retreat to its 52-week low of $41.58, representing a potential loss of approximately -45% from the current price of $74.99. The stock's historical max drawdown of -40.41% provides a benchmark for the magnitude of decline possible in a severe, protracted downturn.
FAQ
The key risks are, in order of severity: 1) Cyclical Demand Risk: The prolonged industry downturn could extend, delaying the return to profitability and pressuring the stock price further (evidenced by -25% YoY revenue decline). 2) Financial Risk: Leverage with a debt-to-equity of 1.58 becomes burdensome during losses, and the dividend cut shows cash preservation is a priority. 3) Valuation/Momentum Risk: The stock's 53% 3-month rally leaves it vulnerable to a sharp correction if recovery hopes fade, with potential downside to the $41.58 52-week low (-45%). 4) Commodity Input Risk: While oil prices have crashed, a rebound or supply disruption (like the March 2026 naphtha issue) could swiftly erase anticipated margin benefits.
The 12-month forecast for LYB is highly dependent on the chemical cycle. Our analysis outlines three scenarios: a Bull Case (30% probability) with a target of $90-$105 on a swift recovery, a Base Case (50% probability) of $70-$85 on a gradual improvement, and a Bear Case (20% probability) of $45-$60 if the downturn persists. The Base Case is most likely, assuming a slow grind higher as fundamentals gradually catch up to the recent price momentum. The key assumption is that lower oil prices will translate to improved gross margins by the second half of 2026, allowing the company to approach the analyst consensus EPS estimate of $5.93.
LYB is fundamentally undervalued on a long-term, normalized earnings basis but may be fairly valued or even overextended in the near term given its recent surge. The trailing Price-to-Sales ratio of 0.46 is near historic lows and suggests the market is assigning a deep discount, pricing in peak cycle pessimism. The forward P/E of 13.1x is reasonable if the earnings recovery materializes. However, the stock's price at 89% of its 52-week high after a massive rally suggests limited margin of safety in the short run. The valuation implies the market expects a meaningful earnings recovery in 2026-2027 but has already priced in a good portion of that optimism.
LYB presents a high-risk, high-reward opportunity that is not suitable for all investors. For a tactical investor with a multi-year horizon who can tolerate volatility, the extreme valuation (PS of 0.46) and market-leading position offer a compelling deep-value case if the chemical cycle recovers. However, given the 53% rally in 3 months and the lack of current profitability, it is a less compelling buy at this moment for most. It would become a more attractive buy on a pullback to the $60-$65 range or upon clear evidence of margin recovery in upcoming earnings. The average analyst target implies significant upside, but this is contingent on achieving estimated EPS of $5.93, which is highly uncertain.
LYB is unsuitable for short-term trading due to its low beta (0.437) which can limit momentum moves, high fundamental uncertainty, and its position near 52-week highs. It is a long-term, cyclical investment requiring a minimum 2-3 year horizon to fully play out the anticipated recovery cycle. The dividend cut removes its appeal for income-focused long-term holders. It is best suited for value-oriented, patient investors willing to buy and hold through volatility while waiting for the cycle to turn. The low beta provides some defensive characteristic, but the stock's fate is tied to industry fundamentals, not short-term market gyrations.